A designer protein binder of KRAS enables exogenous protein degradation
Protein Science · 2026-12 · 35 (12)
DOI: 10.1002/pro.70850 ↗Kurz gefasst
Fachartikel in der Zeitschrift Protein Science, online erschienen am 09.11.2026. Verfasst von Aniekan Okon und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA. Hauptthemen laut MEDLINE: Von Hippel-Lindau Tumor Suppressor Protein, Proteolysis, Proto-Oncogene Proteins p21(ras). Die Arbeit nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIGMS NIH HHS, NIH HHS.
Abstract (Originalsprache)
Targeted protein degradation has emerged as a powerful strategy for modulating intracellular proteins, particularly those lacking traditional small‐molecule binding pockets. While protein‐based degraders expand this approach to undruggable targets, they typically require intracellular expression in target cells, limiting their utility as exogenous research tools. Here, we engineer the Sso7d‐derived KRAS G12D binder R11.1.6 for use as a chemically conjugatable, exogenously deliverable degrader scaffold. We show that a C‐terminal arginine‐to‐cysteine variant can be produced in good yield and purity and conjugated to a von Hippel–Lindau (VHL) E3 ligase ligand, albeit with an approximately 10‐fold reduction in KRAS G12D affinity relative to parent R11. To reduce the number of lysines available for potential ubiquitination, we generate two lysine‐reduced variants—a fully lysine‐free variant (R11 ΔLys ) and a “lysine‐lite” variant retaining only the three lysines implicated in KRAS engagement (R11 Lite )—and demonstrate that both retain nanomolar affinity for wild‐type KRAS and KRAS G12D . Esterification of R11–VHL with an α‐aryl‐α‐diazoamide reagent enables cellular treatment with the chimeric conjugate and leads to VHL‐ligand‐dependent reduction in pan‐RAS levels in HPAF‐II cells, as shown by competition with excess free VHL ligand. Our results establish R11 variants as tractable protein‐engineering scaffolds for developing chemically conjugated biodegraders and provide design principles for engineering lysine‐reduced binders based on the Sso7d scaffold.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Chemistry, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.
- Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.
- Department of Biology, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.
- Koch Institute for Integrative Cancer Research at MIT, Cambridge, Massachusetts, USA.
- Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.
ORCID-Profile: Aniekan Okon, Keith M Cheah, Oscar J Molina, Gabriel Saenz, K Dane Wittrup, Ronald T Raines
Förderung
- NCI NIH HHS
- NIGMS NIH HHS
- NIH HHS
- NIBIB NIH HHS
- National Institutes of Health
Zitieren
APA
Okon, A., Cheah, K. M., Molina, O. J., Saenz, G., Wittrup, K. D., & Raines, R. T. (2026). A designer protein binder of KRAS enables exogenous protein degradation. Protein Science, 35(12). https://doi.org/10.1002/pro.70850
Vancouver
Okon A, Cheah KM, Molina OJ, Saenz G, Wittrup KD, Raines RT. A designer protein binder of KRAS enables exogenous protein degradation. Protein Science. 2026;35(12). doi:10.1002/pro.70850
BibTeX
@article{Okon2026,
author = {Okon, Aniekan and Cheah, Keith M and Molina, Oscar J and Saenz, Gabriel and Wittrup, K Dane and Raines, Ronald T},
title = {A designer protein binder of KRAS enables exogenous protein degradation},
journal = {Protein Science},
year = {2026},
volume = {35},
number = {12},
doi = {10.1002/pro.70850}
}
EUVIMED